Solid tumor therapy using a cannon and pawn combination strategy

Theranostics

Volumn 6, Issue 7, 2016, Pages 1023-1030

  Song, Wantong ^a   Tang, Zhaohui ^a   Zhang, Dawei ^a   Wen, Xue ^b   Lv, Shixian ^a,c   Liu, Zhilin ^a,c   Deng, Mingxiao ^b   Chen, Xuesi ^a  

^a CHANGCHUN INSTITUTE OF APPLIED CHEMISTRY   (China)

^b NORTHEAST NORMAL UNIVERSITY   (China)

^c UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

Combination; Cytotoxic drugs; Nanocarrier; Tumor therapy; Vascular disrupting agents

Indexed keywords

COMBRETASTATIN A4; DOXORUBICIN; NANOCARRIER; ANTINEOPLASTIC AGENT; COMBRETASTATIN A4 PHOSPHATE; DRUG CARRIER; NANOPARTICLE; STILBENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER THERAPY; COLON TUMOR; CONTROLLED STUDY; CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG RELEASE; DRUG TUMOR LEVEL; IN VITRO STUDY; MOUSE; NONHUMAN; SINGLE DRUG DOSE; TUMOR CELL; TUMOR VOLUME; ANIMAL; COLONIC NEOPLASMS; COMBINATION DRUG THERAPY; DISEASE MODEL; METABOLISM; PROCEDURES; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; DOXORUBICIN; DRUG CARRIERS; DRUG THERAPY, COMBINATION; MICE; NANOPARTICLES; STILBENES; TREATMENT OUTCOME;

EID: 84979633657     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.14741     Document Type: Article

References (52)

1. Alexis F, Pridgen EM, Langer R, Farokhzad OC. Nanoparticle technologies for cancer therapy. Handb Exp Pharmacol. 2010; 197: 55-86.
2. Schutz CA, Juillerat-Jeanneret L, Mueller H, Lynch I, Riediker M, Consortium N. Therapeutic nanoparticles in clinics and under clinical evaluation. Nanomedicine (Lond). 2013; 8: 449-67.
3. Hrkach J, Von HoffD, Ali MM, Andrianova E, Auer J, Campbell T, et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med. 2012; 4: 128ra39.
4. Yu H, Guo C, Feng B, Liu J, Chen X, Wang D, et al. Triple-layered pH-responsive micelleplexes loaded with siRNA and cisplatin prodrug for NF-Kappa B targeted treatment of metastatic breast cancer. Theranostics. 2016; 6: 14-27.
5. Peer D, Karp JM, Hong S, FaroKHzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007; 2: 751-60.
6. Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliver Rev. 2013; 65: 71-9.
7. Moon JH, Moxley JW Jr, Zhang P, Cui H. Nanoparticle approaches to combating drug resistance. Future Med Chem. 2015; 7: 1503-10.
8. Momparler RL, Karon M, Siegel SE, Avila F. Effect of adriamycin on DNA, RNA, and protein-synthesis in cell-free systems and intact-cells. Cancer Res. 1976; 36: 2891-5.
9. Dasari S, Tchounwou PB. Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol. 2014; 740: 364-78.
10. Horwitz SB. Taxol (paclitaxel): mechanisms of action. Ann Oncol. 1994; 5(Suppl 6): S3-6.
11. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 2010; 7: 653-64.
12. Lee H, Fonge H, Hoang B, Reilly RM, Allen C. The effects of particle size and molecular targeting on the intratumoral and subcellular distribution of polymeric nanoparticles. Mol Pharmaceut. 2010; 7: 1195-208.
13. Huo S, Ma H, Huang K, Liu J, Wei T, Jin S, et al. Superior penetration and retention behavior of 50 nm gold nanoparticles in tumors. Cancer Res. 2013; 73: 319-30.
14. Wu W, Driessen W, Jiang X. Oligo(ethylene glycol)-based thermosensitive dendrimers and their tumor accumulation and penetration. J Am Chem Soc. 2014; 136: 3145-55.
15. Sykes EA, Chen J, Zheng G, Chan WC. Investigating the impact of nanoparticle size on active and passive tumor targeting efficiency. Acs Nano. 2014; 8: 5696-706.
16. Yuan F, Leunig M, Huang SK, Berk DA, Papahadjopoulos D, Jain RK. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. 1994; 54: 3352-56.
17. Kobayashi H, Watanabe R, Choyke PL. Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target? Theranostics. 2013; 4: 81-9.
18. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res. 1997; 57: 1829-34.
19. Vincent L, Kermani P, Young LM, Cheng J, Zhang F, Shido K, et al. Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J Clin Invest. 2005; 115: 2992-3006.
20. Song W, Tang Z, Zhang D, Li M, Gu J, Chen X. A cooperative polymeric platform for tumor-targeted drug delivery. Chem Sci. 2016; 7: 728-736.
21. Siemann DW, Chaplin DJ, Horsman MR. Vascular-targeting therapies for treatment of malignant disease. Cancer. 2004; 100: 2491-99.
22. Baguley BC, Siemann DW. Temporal aspects of the action of ASA404 (vadimezan; DMXAA). Expert Opin Inv Drug. 2010; 19: 1413-25.
23. Tozer GM, Prise VE, Wilson J, Cemazar M, Shan SQ, Dewhirst MW, et al. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: Intravital microscopy and measurement of vascular permeability. Cancer Res. 2001; 61: 6413-22.
24. Gaya AM, Rustin GJS. Vascular disrupting agents: A new class of drug in cancer therapy. Clin Oncol (R Coll Radiol). 2005; 17: 277-90.
25. Chaplin DJ, Hill SA. The development of combretastatin A4 phosphate as a vascular targeting agent. Int J Radiat Oncol. 2002; 54: 1491-96.
26. Siemann DW, Chaplin DJ, Walicke PA. A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P). Expert Opin Inv Drug. 2009; 18: 189-97.
27. Song W, Tang Z, Zhang D, Yu H, Chen X. Coadministration of vascular disrupting agents and nanomedicines to eradicate tumors from peripheral and central regions. Small. 2015; 11: 3755-61.
28. Galbraith SM, Chaplin DJ, Lee F, Stratford MRL, Locke RJ, Vojnovic B, et al. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res. 2001; 21: 93-102.
29. Grosios K, Holwell SE, McGown AT, Pettit GR, Bibby MC. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer. 1999; 81: 1318-27.
30. Li J, Cona MM, Chen F, Feng Y, Zhou L, Zhang G, et al. Sequential systemic administrations of combretastatin A4 Phosphate and radioiodinated hypericin exert synergistic targeted theranostic effects with prolonged survival on SCID mice carrying bifocal tumor xenografts. Theranostics. 2013; 3: 127-37.
31. Sengupta S, Eavarone D, Capila I, Zhao GL, Watson N, Kiziltepe T, et al. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature. 2005; 436: 568-72.
32. Wang Y, Yang T, Wang X, Dai W, Wang J, Zhang X, et al. Materializing sequential killing of tumor vasculature and tumor cells via targeted polymeric micelle system. J Control Release. 2011; 149: 299-306.
33. Nair LS, Laurencin CT. Biodegradable polymers as biomaterials. Prog Poly Sci. 2007; 32: 762-798.
34. Tian H, Tang Z, Zhuang X, Chen X, Jing X. Biodegradable synthetic polymers: Preparation, functionalization and biomedical application. Prog Poly Sci. 2012; 37: 237-280.
35. He C, Zhuang X, Tang Z, Tian H, Chen X. Stimuli-sensitive synthetic polypeptide-based materials for drug and gene delivery. Adv Healthc Mater. 2012; 1: 48-78.
36. Li C. Poly(L-glutamic acid) -anticancer drug conjugates. Adv Drug Deliver Rev. 2002; 54: 695-713.
37. Nemunaitis J, Cunningham C, Senzer N, Gray M, Oldham F, Pippen J, et al. A. Phase I study of CT-2103, a polymer-conjugated paclitaxel, and carboplatin in patients with advanced solid tumors. Cancer Invest. 2005; 23: 671-76.
38. Koizumi F, Kitagawa M, Negishi T, Onda T, Matsumoto S.-I, Hamaguchi T, et al. Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors. Cancer Res. 2006; 66: 10048-56.
39. Prompruk K, Govender T, Zhang S, Xiong CD, Stolnik S. Synthesis of a novel PEG-block-poly(aspartic acid-stat-phenylalanine) copolymer shows potential for formation of a micellar drug carrier. Int J Pharm. 2005; 297: 242-53.
40. Deng J, Gao N, Wang Y, Yi H, Fang S, Ma Y, et al. Self-assembled cationic micelles based on PEG-PLL-PLLeu hybrid polypeptides as highly effective gene vectors. Biomacromolecules. 2012; 13: 3795-804.
41. Lv S, Li M, Tang Z, Song W, Sun H, Liu H, et al. Doxorubicin-loaded amphiphilic polypeptide-based nanoparticles as an efficient drug delivery system for cancer therapy. Acta Biomater. 2013; 9: 9330-42.
42. Xie Z, Guan H, Chen X, Lu C, Chen L, Hu X, et al. A novel polymer-paclitaxel conjugate based on amphiphilic triblock copolymer. J Control Release. 2007; 117: 210-16.
43. Choe YH, Conover CD, Wu DC, Royzen M, Gervacio Y, Borowski V, et al. Anticancer drug delivery systems: multi-loaded N-4-acyl poly(ethylene glycol) prodrugs of ara-C. II. Efficacy in ascites and solid tumors. J Control Release. 2002; 79: 55-70.
44. Cabral H, Matsumoto Y, Mizuno K, Chen Q, Murakami M, Kimura M, et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol. 2011; 6: 815-23.
45. Tang L, Yang XJ, Yin Q, Cai KM, Wang H, Chaudhury I, et al. Investigating the optimal size of anticancer nanomedicine. P Natl Acad Sci USA. 2014; 111: 15344-49.
46. Wang J, Mao W, Lock LL, Tang J, Sui M, Sun W, et al. The role of micelle size in tumor accumulation, penetration, and treatment. ACS Nano. 2015; 9: 7195-206.
47. Sun Q, Sun X, Ma X, Zhou Z, Jin E, Zhang B, et al. Integration of nanoassembly functions for an effective delivery cascade for cancer drugs. Adv Mater. 2014; 26: 7615-21.
48. Du JZ, Sun TM, Song WJ, Wu J, Wang J. A tumor-acidity-activated charge-conversional nanogel as an intelligent vehicle for promoted tumoral-cell uptake and drug delivery. Angew Chem Int Ed Engl. 2010; 49: 3621-26.
49. Zhou Z, Shen Y, Tang J, Fan M, Van Kirk EA, Murdoch WJ, et al. Charge-reversal drug conjugate for targeted cancer cell nuclear drug delivery. Adv Funct Mater. 2009; 19: 3580-89.
50. Wu J, Akaike T, Maeda H. Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger. Cancer Res. 1998; 58: 159-65.
51. Holash J, Wiegand SJ, Yancopoulos GD. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene. 1999; 18: 5356-62.
52. GraffBA, Benjaminsen IC, Brurberg KG, Ruud EBM, Rofstad EK. Comparison of tumor blood perfusion assessed by dynamic contrast-enhanced MRI with tumor blood supply assessed by invasive imaging. J Magn Reson Imaging. 2005; 21: 272-81.